Day 2

Final

Time: Central European Time (CET)



09.00 – 09.45 OPENING SPEECHES
Conference
Moderators:
Dimitrios ATHANASIOU, EMA Pediatric Committee , EPF, WDO, EAE Board Member
Vasilis KARATZIAS, President, Hellenic Friedreich’s Ataxia Association, Director of the Office of Legal Advisers, NATO Rapid Deployable Corps, Greece
Speakers: Norbert COUESPEL, Chair, Future-Proofing Health Systems Committee, European Health Parliament, 7th edition
Konstantinos HATZIDAKIS, Minister for Labor and Social Affairs, Greece
Violeta STOYANOVA-BENINSKA, MD, PhD, MPH Chair of the Committee for Orphan Medicinal Products (COMP), European Medicines Agency (EMA)
Alexander NATZ, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)
Flaminia MACCHIA, Executive Director, Rare Diseases International
09.45  SESSION 5 | THINKING OUT OF THE BOX: ALTERNATIVE ACCESS AND FUNDING MODELS FOR RARE DISEASES
09.45 – 10.00 KEYNOTE SPEECH: RARE IMPACT
Simone BOSELLI, Public Affairs Director, EURORDIS-Rare Diseases Europe
10.00 – 11.00 A. TRANSFORMING ACCESS MODELS FOR RDS
Moderator: Alexander ΝΑΤΖ, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)
Panel Discussion: Declan NOONE, President of the European Haemophilia Consortium (EHC)
  Thomas BOLS, Head of Government Affairs and Public Policy, EMEA & APAC, PTC Therapeutics
  Ana HIDALGO-SIMON, Head of Advanced Therapies Human Medicines Division, European Medicines Agency (EMA)
Discussion – Q&A
11.00 – 12.00 B. NEW ACCESS MODELS FOR RD MEDICINES
Moderator: Anja SCHIEL, Chair, Scientific Advice Working Party, EMA, Vice Chair EUnetHTA21, Senior Advisor Norwegian Medicines Agency (NoMA)
Keynote Speech: Alexander ΝΑΤΖ, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)
Panel Discussion: Nerea BLANQUÉ-CATALINA, Senior Vice President Market Access and Pricing, Alira Health
Jamie O’ HARA, CEO, HCD Economics
Maciej GAJEWSKI, Executive Director, Head of International Government Affairs and Policy, Alexion Pharmaceuticals
Discussion – Q&A
12.00 – 13.00 Expo – Networking Break
13.00 – 14.00  C. NEW FUNDING MODELS FOR ACCESS
Moderator: Simone BOSELLI, Public Affairs Director, EURORDIS-Rare Diseases Europe
Keynote Speech: The European Perspective on a New Funding for Access to Rare Disease Treatments
Tomislav SOKOL, MEP, EPP Group in the European Parliament
Panel Discussion: The Oslo Medicines Initiative
Stanislav KNIAZKOV, Technical Officer, Medical Product Regulation at World Health Organization (WHO)
Eleni ANTONIOU, Senior Policy Officer, Thalassaemia International Federation (TIF)
Fernando ARNAIZ, Global Access & Healthcare Funding & Financing solutions lead, Roche
Discussion – Q&A
14.00 – 15.30 D.  NEW FUNDING MODELS FOR RD DRUG DEVELOPMENT
Moderator: Duane SCHULTHESS, Managing Director of Vital Transformation
Keynote Speech: Rare Disease Mega funds
Andrew W. LO, Charles E. and Susan T. Harris Professor, Professor, Finance, Director, Laboratory for Financial Engineering, MIT Sloan School of Management
Panel Discussion: Richard MASON, CEO Apollo Therapeutics
Devin ROSENTHAL, PhD. Vice President NovaQuest Capital Management
Gergely KRAJCSI, Investment Officer, Growth Capital & Innovation Finance Unit, European Investment Bank (EIB)
Maria da Graça CARVALHO, Member of the European Parliament 
Discussion – Q&A
15.30 – 16.00 Expo – Networking Break
16.00 – 17.30 SESSION 6 | RARE DISEASES AS A NATIONAL PRIORITY IN GREECE
Designing and implementing national policies, strategies, and programs with the aim of contributing to the well-being and fulfilling the rights of all people living with a rare disease in Greece. 
Moderators: Dimitrios ATHANASIOU, EMA Pediatric Committee , EPF, WDO, EAE Board Member
Vasilis KARATZIAS, President, Hellenic Friedreich’s Ataxia Association, Director of the Office of Legal Advisers, NATO Rapid Deployable Corps, Greece
Panel Discussion: Mina GAGA, MD, PhD Alternate Minister of Health, Ministry of Health, Greece
Giannis SOTIRIOU, CeO IFET
Michael HIMONAS, General Manager of the Hellenic Association of Pharmaceutical Companies (SFEE)
Dimitrios BOUMPAS, Professor of Pathology-Rheumatology, Medical School, National Kapodistrian University of Athens, President of the Central Health Council (KESY), President of the Medical Society of Athens, Director of the 4th Pathological Clinic, General University Hospital of Athens “ATTIKON”, Member of the Institute of Molecular Biology and Biotechnology, Crete and the Institute of Biomedical Research, Academy of Athens, Greece
Nikos KOSTARAS, General Manager, IQVIA Greece
Pavlina KARASIOTOU, Secretary General of Social Insurance, Ministry for Labor and Social Affairs
Athanassios VOZIKIS, Associate Professor, Laboratory of Health Economics and Management, Economics Department, University of Piraeus
Discussion – Q&A
17.30 END OF DAY 2

Contact us


Registrations
Greece: Chrysoula Kordouli, Τ: +30 210 6617777 (ext. 204), +30 6946236795, E: [email protected]
Cyprus: Ioanna Antoniou, Τ: +357 99 494 653, E: [email protected]
 
Sponsorships
Greece: Chrysoula Kordouli, Τ: +30 210 6617777 (ext. 204), +30 6946236795, E: [email protected]
Cyprus: Giorgos Loizou, Τ: +357 99 103323, E: [email protected]
 
Info & Content
Natalia Toubanaki, T: +30 210 6617 777 (ext. 289), +306947936708, E: [email protected]

BOUSSIAS

  338. Kleisthenous Str. 15344, Gerakas, Attiki, Greece
  +30 210 6617777
  +30 210 6617778
  www.boussias.com